We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

ZEUS SCIENTIFIC

ZEUS Scientific provides high-performing, easy-to-use clinical diagnostic solutions. The company’s products are desig... read more Featured Products: More products

Download Mobile App





ZEUS Receives FDA EUA Approval for SARS-SoV-2 Tests on Dynex Instruments

By LabMedica International staff writers
Posted on 13 Sep 2021
ZEUS Scientific (Branchburg, NJ, USA) has received FDA authorization to run the ZEUS ELISA SARS-SoV-2 Total Antibody Test System using the Dynex Agility, Dynex DSX or Dynex DS2 Automated ELISA Systems from Dynex Technologies (Chantilly, VA, USA).

The ZEUS ELISA SARS-CoV-2 IgG Test System assay utilizes a dual antigen combination of recombinant S1 receptor binding domain (RBD) viral protein and recombinant nucleoprotein that detects immune responses that other antibody tests may miss.

The SARS-CoV-2 IgG Test system was first granted EUA in October of 2020 to run the ZEUS SARS-CoV-2 IgG Test System manually or using the Dynex Agility Automated ELISA System. More...
The FDA has extended the EUA to include the Dynex DS2 and Dynex DSX automated ELISA systems.

Related Links:
ZEUS Scientific
Dynex Technologies



Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Chromogenic Culture System
InTray™ COLOREX™ ECC
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.